勘误：循环中高浓度的音猬因子蛋白与接受酪氨酸激酶抑制剂治疗的EGFR突变晚期非小细胞肺癌的不良预后相关。
Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.
作者信息
Takam Kamga Paul, Swalduz Aurélie, Costantini Adrien, Julié Catherine, Emile Jean-François, Pérol Maurice, Avrillon Virginie, Ortiz-Cuaran Sandra, De Saintigny Pierre, Giroux-Leprieur Etienne
机构信息
Université Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.
Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
出版信息
Front Oncol. 2022 Feb 9;12:852540. doi: 10.3389/fonc.2022.852540. eCollection 2022.
Abstract
[This corrects the article DOI: 10.3389/fonc.2021.747692.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2021.747692。]
相似文献
1
Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.勘误：循环中高浓度的音猬因子蛋白与接受酪氨酸激酶抑制剂治疗的EGFR突变晚期非小细胞肺癌的不良预后相关。
Front Oncol. 2022 Feb 9;12:852540. doi: 10.3389/fonc.2022.852540. eCollection 2022.
2
High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.循环中 Sonic Hedgehog 蛋白水平高与酪氨酸激酶抑制剂治疗的 EGFR 突变晚期非小细胞肺癌预后不良相关。
Front Oncol. 2021 Dec 14;11:747692. doi: 10.3389/fonc.2021.747692. eCollection 2021.
3
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.表皮生长因子受体酪氨酸激酶抑制剂治疗前后表皮生长因子受体突变的非小细胞肺癌中的肿瘤免疫微环境：一篇叙述性综述
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
4
Activation of the Hedgehog pathway mediates resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer.刺猬信号通路的激活介导非小细胞肺癌对表皮生长因子受体抑制剂的耐药性。
J Cancer. 2022 Jan 4;13(3):987-997. doi: 10.7150/jca.63410. eCollection 2022.
5
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
6
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.抑制Hedgehog信号通路可协同增强非小细胞肺癌细胞系对表皮生长因子受体酪氨酸激酶抑制剂的敏感性。
PLoS One. 2016 Mar 4;11(3):e0149370. doi: 10.1371/journal.pone.0149370. eCollection 2016.
7
Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.悉尼西南部地方卫生区晚期表皮生长因子受体突变型非小细胞肺癌患者的临床结局
Intern Med J. 2017 Dec;47(12):1405-1411. doi: 10.1111/imj.13555.
8
The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.晚期非小细胞肺癌患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）疗效的相关性：94例EGFR突变患者的回顾性评估
Oncotarget. 2017 Jan 10;8(2):3412-3421. doi: 10.18632/oncotarget.13787.
9
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.在表皮生长因子受体酪氨酸激酶抑制剂治疗后出现脑膜转移的 EGFR 突变型非小细胞肺癌中重新挑战治疗。
Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14.
10
Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.表皮生长因子受体靶向免疫磁脂质体用于表皮生长因子受体酪氨酸激酶抑制剂治疗的非小细胞肺癌循环肿瘤细胞计数。
Lung Cancer. 2019 Jun;132:45-53. doi: 10.1016/j.lungcan.2019.04.003. Epub 2019 Apr 5.
Zotero 插件